胃癌（GC）是全球最常见的癌症之一。最近的研究表明，tsRNAs在GC中起着重要作用，并且tsRNA表达水平的变化可用于GC的诊断和治疗反应预测。采用风险比（HR）、比值比（OR）和95%置信区间（CI）评估tsRNA表达与GC患者预后和其他临床病理特征的相关性。通过分析敏感度、特异度、受试者工作特征曲线下面积（AUC）和诊断比值（DOR），评价tsRNAs的诊断价值。结果表明，tsRNA上调的患者预后较差（HR = 2.48，95% CI: 1.85-3.34），而tsRNA下调的患者预后较好（HR = 0.55，95% CI: 0.31-0.98）。此外，tsRNA表达与GC患者的各种临床病理特征显著相关。最后，在诊断研究中，与健康对照组相比（AUC = 0.81，DOR = 7.74），GC相关的tsRNAs能够将炎症患者（AUC = 0.74，DOR = 4.44）区分开。tsRNAs在GC诊断和预后评估中具有潜在的临床应用价值。有必要进一步评估和验证其他特异性tsRNAs作为GC标志物的可行性和实用性。

Gastric cancer (GC) is one of the most common types of cancer worldwide. Recent studies have shown that tsRNAs play important roles in GC and that changes in the expression levels of tsRNAs can be used for GC diagnosis and treatment response prediction.Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the correlation between tsRNA expression and prognosis and other clinicopathologic features of GC patients. The sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and diagnostic odds ratio (DOR) were analyzed to evaluate the diagnostic value of tsRNAs.The results showed that patients with tsRNA upregulation had a poor prognosis (HR = 2.48, 95% CI: 1.85-3.34), while patients with tsRNA downregulation had a favorable prognosis (HR = 0.55, 95% CI: 0.31-0.98). In addition, tsRNA expression was significantly correlated with various clinicopathological features in patients with GC. Finally, in diagnostic studies, GC-related tsRNAs could differentiate healthy controls (AUC = 0.81, DOR = 7.74) from patients with inflammation (AUC = 0.74, DOR = 4.44).tsRNAs have potential clinical application in GC diagnosis and prognosis evaluation. It is necessary to further assess and verify the practicability and feasibility of additional specific tsRNAs as GC markers in the future.